DESIGNED TO PREVENT MIGRAINE*1
AQUIPTA is a simple once-daily tablet that works fast† to prevent migraine1,2
*In 3-month clinical studies, AQUIPTA significantly reduced monthly migraine days.1
†In a clinical study, 87.7% of patients who received AQUIPTA 60 mg did not have a migraine the day after the first dose compared to 74.8% on placebo.2
AQUIPTA® (atogepant) is a privately-funded prescription medicine used to prevent migraine in patients who have at least 4 migraine days per month. It is available at a discounted price through Airport Oaks Pharmacy.3
The preventative power of AQUIPTA
Works fast* to prevent migraine attacks2
*In a clinical study, 87.7% of patients who received AQUIPTA 60 mg did not have a migraine the day after the first dose compared to 74.8% on placebo.2
Fewer monthly migraine days†1
†In 3-month clinical studies, AQUIPTA significantly reduced monthly migraine days.1
What types of migraine can AQUIPTA help with?1
Episodic migraine
People who get 4–14 migraine days per month.
Chronic migraine
People who experience ≥15 headache days per month with ≥8 migraine days.*
*Monthly headache days refer to any day a headache occurs, while monthly migraine days refer to days that specifically meet the criteria for a migraine attack.
How does AQUIPTA work?3-6
Your body has a protein called calcitonin gene-related peptide, or CGRP. CGRP is believed to play a major role in migraine attacks, causing pain and inflammation.
AQUIPTA is designed to block CGRP, and by doing so, it helps to prevent a migraine from occurring.
By taking a tablet once daily, even when you are not experiencing a migraine, you can help keep migraine attacks away. Some people may notice improvements within the first week, while for others, the effects of AQUIPTA may build gradually over 12 weeks or longer.1,2
The person shown is from stock photography (model) and is not an actual patient.
References: 1. AQUIPTA® (atogepant) Data Sheet. 2. Schwedt TJ et al. Cephalalgia 2022;42(1):3–11. 3. AQUIPTA® (atogepant) Consumer Medicine Information. 4. Russo AF. Annu Rev Pharmacol Toxicol 2015;55:533–552. 5. Edvinsson L et al. Nat Rev Neurol 2018;14(6):338–350. 6. Edvinsson L. Headache 2017;57(suppl 2):47–55.
NZ-AQP-240017. AQU-005305-01. January 2026.
